This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
S Akhondzadeh , M Tabatabaee , H Amini , SA Ahmadi Abhari , (2007). Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophrenia Research 90, 179–185.
NC Andreasen , M Flaum , S Arndt (1992). The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Archives of General Psychiatry 49, 615–623.
DE Ayer , RN Eisenman (1993). A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. Genes & Development 7, 2110–2119.
E Beillard , N Pallisgaard , VH van der Velden , W Bi , (2003). Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program. Leukemia 17, 2474–2486.
AB Birkenaes , S Opjordsmoen , C Brunborg , JA Engh , (2007). The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. Journal of Clinical Psychiatry 68, 917–923.
V Blank (2008). Small Maf proteins in mammalian gene control: mere dimerization partners or dynamic transcriptional regulators? Journal of Molecular Biology 376, 913–925.
E Bramon , PC Sham (2001). The common genetic liability between schizophrenia and bipolar disorder: a review. Current Psychiatry Reports 3, 332–337.
JH Carter , WG Tourtellotte (2007). Early growth response transcriptional regulators are dispensable for macrophage differentiation. Journal of Immunology 178, 3038–3047.
S Collins , MA Lutz , PE Zarek , RA Anders , (2008). Opposing regulation of T cell function by Egr-1/NAB2 and Egr-2/Egr-3. European Journal of Immunology 38, 528–536.
D de Ridder , FJ Staal , JJ van Dongen , MJ Reinders (2006). Maximum significance clustering of oligonucleotide microarrays. Bioinformatics 22, 326–331.
RC Drexhage , RC Padmos , H de Wit , MA Versnel , (2008). Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: association with the metabolic syndrome in patients? Schizophrenia Research 102, 352–355.
L Drzyzga , E Obuchowicz , A Marcinowska , ZS Herman (2006). Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain, Behaviour and Immunity 20, 532–545.
WW Eaton , M Byrne , H Ewald , O Mors , (2006). Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. American Journal of Psychiatry 163, 521–528.
PJ Hurlin , J Huang (2006). The MAX-interacting transcription factor network. Seminars in Cancer Biology 16, 265–274.
EM Knijff , MN Breunis , MC van Geest , RW Kupka , (2006). A relative resistance of T cells to dexamethasone in bipolar disorder. Bipolar Disorder 8, 740–750.
P Lichtenstein , BH Yip , C Bjork , Y Pawitan , (2009). Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 373, 234–239.
PA Lyons , M Koukoulaki , A Hatton , K Doggett , (2007). Microarray analysis of human leucocyte subsets: the advantages of positive selection and rapid purification. BMC Genomics 8, 64.
SD Martina , MS Ismail , KS Vesta (2006). Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease. Annals of Pharmacotherapy 40, 1822–1828.
H Motohashi , JA Shavit , K Igarashi , M Yamamoto , (1997). The world according to Maf. Nucleic Acids Research 25, 2953–2959.
N Muller , MJ Schwarz , S Dehning , A Douhe , (2006). The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Molecular Psychiatry 11, 680–684.
N Muller , M Ulmschneider , C Scheppach , MJ Schwarz , (2004). COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. European Archives of Psychiatry & Clinical Neuroscience 254, 14–22.
AM Myint , HW Steinbusch , L Goeghegan , D Luchtman , (2007). Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. Neuroimmunomodulation 14, 65–71.
FG Nery , ES Monkul , JP Hatch , M Fonseca , (2008). Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Human Psychopharmacology 23, 87–94.
MJ Owen , N Craddock (2009). Diagnosis of functional psychoses: time to face the future. Lancet 373, 190–191.
RC Padmos , L Bekris , EM Knijff , H Tiemeier , (2004). A high prevalence of organ-specific autoimmunity in patients with bipolar disorder. Biological Psychiatry 56, 476–482.
RC Padmos , MH Hillegers , EM Knijff , R Vonk , (2008 a). A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Archives of General Psychiatry 65, 395–407.
RC Padmos , NC Schloot , H Beyan , C Ruwhof , (2008 b). Distinct monocyte gene-expression profiles in autoimmune diabetes. Diabetes 57, 2768–2773.
T Pollmacher , M Haack , A Schuld , T Kraus , (2000). Effects of antipsychotic drugs on cytokine networks. Journal of Psychiatric Research 34, 369–382.
RS Smith , M Maes (1995). The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Medical Hypotheses 45, 135–141.
FJ Staal , F Weerkamp , MR Baert , CM van den Burg , (2004). Wnt target genes identified by DNA microarrays in immature CD34+ thymocytes regulate proliferation and cell adhesion. Journal of Immunology 172, 1099–1108.
T Suppes , GS Leverich , PE Keck , WA Nolen , (2001). The stanley foundation bipolar treatment outcome network. II. Demographics and illness characteristics of the first 261 patients. Journal of Affective Disorders 67, 45–59.
PA Thomson , NR Wray , JK Millar , KL Evans , (2005). Association between the TRAX/DISC locus and both bipolar disorder and schizophrenia in the Scottish population. Molecular Psychiatry 10, 657–668, 616.
S Tyring , A Gottlieb , K Papp , K Gordon , (2006). Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367, 29–35.
R Vonk , AC van der Schot , RS Kahn , WA Nolen , (2007). Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder? Biological Psychiatry 62, 135–140.
J Zhu , E Mix , B Winblad (2001). The antidepressant and antiinflammatory effects of rolipram in the central nervous system. CNS Drug Reviews 7, 387–398.